Anna Di Benedetto
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications
Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study.
Journal: NPJ breast cancer
Published: January 23, 2026
Multi-omics analyses integration reveals a novel TRF2-miR-181a-5p-S100A10 regulatory axis in colon cancer.
Journal: Cellular & molecular biology letters
Published: January 31, 2025
Author Correction: Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.
Journal: Nature immunology
Published: September 17, 2024
DNA Damage Response in Early Breast Cancer: A Phase III Cohort in the Phobos Study.
Journal: Cancers
Published: June 26, 2024
TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication.
Journal: Journal of experimental & clinical cancer research : CR
Published: December 27, 2023
Changes in sleep performance and chronotype behaviour after vestibular rehabilitation in unilateral vestibular hypofunction.
Journal: The Journal of laryngology and otology
Published: December 16, 2022
The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study.
Journal: Cancers
Published: September 07, 2022
A Real-World Systematic Analysis of Driver Mutations' Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting.
Journal: Cancers
Published: March 09, 2022
Not enough can be enough: feasibility of the Idylla EGFR mutation test when reuse of stained tissue slides is the only option available.
Journal: Journal of clinical pathology
Published: June 03, 2021
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.
Journal: Nature immunology
Published: April 18, 2021
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.
Journal: Scientific reports
Published: August 22, 2020
Last Updated: 09/26/2026